Tcr2 Therapeutics Inc.

Werewolf Therapeutics, Inc.

Harpoon Therapeutics, Inc.

Micromet Ag

Amgen Inc.

Amgen Research (munich) Gmbh

Other

Takeda Pharmaceutical Company Limited

Tularik Limited

Tcr2 Therabeutics Inc.

Patrick A Baeuerle

Luke Evnin

Robert Hofmeister

Gregory Sieczkiewicz

Holger Wesche

Vinay Bhaskar

Daniel Hicklin

William Winston

Cynthia Seidel-Dugan

Heather R Brodkin

Jose Andres Salmeron Garcia

Jeanmarie Guenot

Peter Kufer

Robert B Dubridge

Bryan D Lemon

Richard J Austin

Vanitha Ramakrishnan

Bei Shan

Jin-Long Chen

Andreas Wolf

Matthias Klinger

Holger Beckmann

Christian Itin

Pui Seto

Meera Berry

Kevin Lustig

Eugen Leo

Peter S Linsley

Tobias Raum

Mark Leo Michaels

Wei Yan

Gerhard Zugmaier

Dirk Nagorsen

Sonja Offner

Birgit Kohleisen

Maia Vinogradova

Anand Panchal

Thomas Urbig

Klaus Brischwein

Marcel Zocher

Torsten Dreier

Luis G Borges

Frank Hanakam

Nadja Prang

The disclosure features fusion proteins that are conditionally active variants of IL-12. In one aspect, the full-length polypeptides of the invention have reduced or minimal cytokine-receptor activating activity even though they contain a functional cytokine polypeptide. Upon activation, e.g., by cleavage of a linker that joins a blocking moiety, e.g., a steric blocking polypeptide, in sequence to the active cytokine, the cytokine can bind its receptor and effect signaling.

Activatable interleukin 12 polypeptides and methods of use thereof

The invention relates to COnditional Bispecific Redirected Activation constructs, or COBRAs, that are administered in an active pro-drug format. Upon exposure to tumor proteases, the constructs are cleaved and activated, such that they can bind both tumor target antigens (TTAs) as well as CD3, thus recruiting T cells expressing CD3 to the tumor, resulting in treatment.

Constrained conditionally activated binding proteins

Provided herein are trispecific antigen-binding proteins comprising a domain binding to CD3, a half-life extension domain, and a domain binding to a target antigen. Also provided are pharmaceutical compositions thereof, as well as nucleic acids, recombinant expression vectors and host cells for making such trispecific antigen-binding proteins. Also disclosed are methods of using the disclosed trispecific antigen-binding proteins in the prevention, and/or treatment diseases, conditions and disorders.

Trispecific binding proteins and methods of use

The disclosure features fusion proteins that are conditionally active variants of IL-2. In one aspect, the full-length polypeptides of the invention have reduced or minimal cytokine-receptor activating activity even though they contain a functional cytokine polypeptide. Upon activation, e.g., by cleavage of a linker that joins a blocking moiety, e.g., a steric blocking polypeptide, in sequence to the active cytokine, the cytokine can bind its receptor and effect signaling.

Activatable interleukin-2 polypeptides and methods of use thereof

Provided herein are T-cell receptor (TCR) fusion proteins (TFPs), T-cells engineered to express one or more TFPs, and methods of use thereof for the treatment of diseases, including cancer.

Compositions and methods for TCR reprogramming using fusion proteins

Provided herein are T-cell receptor (TCR) fusion proteins (TFPs) having specificity for one or more tumor cell associated antigens, T cells engineered to express one or more TFP, and methods of use thereof for the treatment of diseases, including cancer.

Described herein is a bispecific molecule containing an Fc polypeptide chain and immunoglobulin variable regions. Also provided are pharmaceutical formulations comprising such molecules, nucleic acids encoding such molecules, host cells containing such nucleic acids, methods of making such molecules, and methods of using such molecules.

Bispecific-Fc molecules

Disclosed herein are inducible monovalent target-binding proteins which are activated upon protease cleavage. Pharmaceutical compositions comprising the binding proteins disclosed herein and methods of using such formulations are further provided.

Inducible monovalent antigen binding protein

Provided are pharmaceutical means and methods for the prevention, treatment or amelioration of indolent or aggressive B cell non-Hodgkin lymphoma (B NHL) and B cell leukemia comprising the administration of a bispecific single chain antibody construct to a subject in the need thereof and the use of said bispecific single chain antibody construct for the preparation of a pharmaceutical composition for the prevention, treatment or amelioration of indolent or aggressive B cell non-Hodgkin lymphoma (B NHL) and B cell leukemia, whereby said construct is to be administered for at least 1 week in specified daily doses. Moreover, the invention relates to kits comprising a bispecific single chain antibody construct to be used in accordance with this invention.

Means and methods for the treament of B cell non-hodgkin lymphoma and B cell leukemia

Growing community of inventors

Gauting, Germany

Patrick A Baeuerle